CNSide Diagnostics, a wholly-owned subsidiary of Plus Therapeutics (PSTV), has signed a national agreement with Humana (HUM), effective October 29, covering approximately 16M people throughout the United States, to provide the CNSide Cerebrospinal Fluid Tumor Cell Enumeration laboratory developed test. This brings CNSide CSF TCE LDT total policy coverage to 67M people.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTV:
- Plus Therapeutics Gains Nasdaq Extension for Compliance
- Plus receives additional extension to regain compliance with Nasdasq
- Plus Therapeutics highlights ReSPECT-LM trial results at SITC meeting
- Buy Rating for Plus Therapeutics: Growth Potential Driven by CNSide Launch and Strategic Positioning
- Plus Therapeutics price target lowered to $2 from $3 at H.C. Wainwright